US 11,730,719 B2
Pharmaceutical composition
Shin Sugimoto, Fuji (JP); and Akito Minamizono, Fuji (JP)
Assigned to KOWA COMPANY, LTD., Nagoya (JP)
Filed by KOWA COMPANY, LTD., Nagoya (JP)
Filed on Feb. 2, 2022, as Appl. No. 17/591,108.
Application 17/591,108 is a continuation of application No. 16/627,178, granted, now 11,298,340, previously published as PCT/JP2018/024887, filed on Jun. 29, 2018.
Claims priority of application No. 2017-129306 (JP), filed on Jun. 30, 2017.
Prior Publication US 2022/0151996 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/423 (2006.01)
CPC A61K 31/423 (2013.01) 8 Claims
 
1. A pharmaceutical composition comprising a pemafibrate crystal, wherein the pemafibrate crystal has a peak at one or more diffraction angles (2θ) selected from the group consisting of around 7.3±0.2°, around 14.6±0.2°, around 15.3±0.2°, around 16.2±0.2°, around 18.2±0.2°, around 18.9±0.2°, around 20.6±0.2°, around 21.5±0.2°, around 22.5±0.2° and around 24.1±0.2° in a powder X-ray diffraction pattern obtained by irradiation with Cu-Kα radiation.